Quest Diagnostics Raises Guidance on Strong Q1, Signals Continued Growth
Event summary
- Quest Diagnostics reported Q1 2026 revenues of $2.90 billion, up 9.2% year-over-year, with 9.0% organic revenue growth.
- The company’s adjusted diluted EPS increased 13.1% to $2.50 for Q1 2026.
- Quest Diagnostics raised its full-year 2026 revenue and EPS guidance, expecting reported diluted EPS between $9.58 and $9.78 and adjusted diluted EPS between $10.63 and $10.83.
- The company is advancing Co-Lab Solutions and a joint venture laboratory with Corewell Health, expanding beyond Fresenius Medical Care for lab and water purity testing.
The big picture
Quest Diagnostics' strong Q1 performance and raised guidance reflect a broader trend of increased demand for diagnostic services, fueled by both clinical and consumer channels. The company's focus on innovation, particularly in advanced diagnostics and AI-powered tools, positions it to capitalize on this trend, but also exposes it to the risks associated with rapidly evolving technologies and competitive pressures within the healthcare sector. The expansion of partnerships, like the one with Corewell Health, highlights a shift towards collaborative models in healthcare delivery.
What we're watching
- Execution Risk
- The success of Project Nova, a multi-year initiative to transform order-to-cash processes, will be critical to sustaining operational efficiency gains, and the fall 2027 implementation date represents a key milestone.
- Consumer Channel
- Continued robust growth in the consumer channel, driven by questhealth.com and collaborations, will depend on maintaining competitive pricing and effectively marketing diagnostic services directly to consumers.
- Partnership Dynamics
- The evolving relationships with partners like Corewell Health and City of Hope will shape Quest’s ability to expand its service offerings and drive innovation in areas like Alzheimer’s disease and cancer monitoring.
Related topics